Appropriate Use Criteria to Reduce Underuse and Overuse of Revascularization
Although the appropriate use criteria (AUC) for the performance of revascularization are well meaning, important limitations include the facts that they: 1) represent the consensus of a limited group of stakeholders; 2) classify a minority of possible permutations of patient scenarios; 3) do not incorporate essential data points, including specific lesion characteristics, extent of myocardium supplied, fractional flow reserve and intravascular ultrasound data, and important comorbidities (diabetes mellitus, chronic kidney disease, and so forth); 4) are based on data recording in the National Cardiovascular Data Registry by persons with widely variable training and motivation without systematic monitoring, adjudication, or audit; 5) undervalue quality of life issues, and in this regard, ignore patient preferences; and 6) do not emphasize underuse of percutaneous coronary intervention (1) (2) (3) (4) .
In this regard, Ko et al. (5) report that almost one-third of subjects undergoing angiography in Ontario, Canada, between April 2006 and March 2007 deemed "appropriate" by U.S. AUC criteria were not revascularized. Such patients experienced appreciably worse clinical outcomes (increased incidence of death or acute coronary syndrome presentation) through 3-year follow-up (hazard ratio [HR] of revascularization vs. medical therapy: 0.61; 95% confidence interval [CI]: 0.42 to 0.88). In the accompanying editorial, Patel (6) states: "This reduction in clinical events was not seen in patients with a revascularization classification (appropriateness score) of uncertain (HR: 0.57; 95% CI: 0.28 to 1.16) or inappropriate (HR: 0.99; 95% CI: 0.48 to 2.02)" (6) .
Although we agree with Dr. Patel regarding the apparent lack of benefit associated with revascularization (vs. medical therapy) in subjects scored as inappropriate (at least as regards death or new acute coronary syndrome, although chronic angina and quality of life data were not collected), we disagree with the conclusion for the "uncertain" patients. Given the point estimate and confidence interval, this may well represent type II error. As evident from the nearly identical HRs, the magnitude of benefit provided by revascularization (vs. medical therapy) may be at least as great among the "uncertain" and "appropriate" classified cohorts, but was obscured by the relative lack of power (only 326 subjects classified as uncertain vs. 991 subjects classified as appropriate). Upsizing the uncertain cohort to 991 subjects, with proportionally similar event rates for revascularized (8%; 43 events) and medically treated (15.3%; 70 events) subjects, results in an odds ratio for revascularization (vs. medical therapy) of 0.48 (95% CI: 0.31 to 0.73), a highly statistically significant difference. Thus, on the basis of this report, larger studies are warranted to determine whether the spectrum of patients benefitting from revascularization should expand to include the uncertain group (which would further enlarge the specter of underuse).
Reply
We appreciate the insightful comments provided by Drs. Kereiakes and Stone on our study (1) . Applying the appropriate use criteria of coronary revascularization on patients with stable coronary artery disease afforded new insights on the potential overutilization, underutilization, and uncertain use of coronary revascularization in contemporary practice (2) . In our population-based cohort assembled in Ontario, Canada, we observed the majority (68%) of coronary revascularizations were considered appropriate, 18% were considered uncertain, and 14% were considered inappropriate. Among patients who had appropriate indications, we found that coronary revascularization was associated with a 39% lower hazard of adjusted death or repeat acute coronary syndrome at 3 years. We also observed that 31% of patients in the appropriate category did not receive revascularization, suggesting that underutilization of therapy is still prevalent in clinical practice. In contrast, patients who had inappropriate indications and received coronary revascularization or medical therapy had no significant difference in hazard of death or acute coronary syndrome, suggesting potential overutilization of coronary revascularization in this subgroup. Finally, many clinical scenarios in the appropriateness use criteria were categorized as uncertain for coronary revascularization because of the equipoise of scientific evidence. Whereas we did not find significant differences in the adjusted rates of clinical outcomes among patients with uncertain indications, the hazard ratio was 0.61 (95% confidence interval: 0.28 to 1.16), suggesting a possible benefit of coronary revascularization. We believe there is an urgent need to understand factors associated with underutilization and overutilization of coronary revascularization. We also completely agree that larger, more comprehensive studies of patients in the uncertain category should be undertaken in the future to more definitively assess whether these types of patients derive benefit from coronary revascularization procedures.
Continued debate and discussion of concerns around the appropriate use criteria (AUC) for revascularization such as those expressed by Drs. Kereiakes and Stone are essential in continuing to improve the process and application of the criteria (1). However, the concerns expressed and perspectives should be examined in light of the existing data with the AUC for revascularization.
With regards to the general limitations noted, several of the lines of data and perspectives may provide the view that the AUC glass is indeed "three-quarters full" rather than "mostly empty" as implied by the authors. Specifically, 1) the AUC do not represent a limited set of stakeholders, rather they involve representation from all of the cardiovascular professional societies and several reviewing organizations, and they represent the only existing criteria or recommendations that have been surveyed and found to have over 80% agreement with interventional cardiologists who have not gone through the evidence or review process (2). 2) Rather than "classifying a minority" patient scenario, the AUC in their current form have been shown to categorize in the NCDR (National Cardiovascular Data Registry) review by Chan Drs. Kereiakes and Stone also have a misunderstanding of the AUC, in that the goal of the AUC is to ensure the appropriate use of revascularization aimed at improving patient health status and clinical outcomes, reducing both underuse and overuse. Notably, no practice document such as the AUC or clinical practice guidelines can capture the varied array of potential patient preferences; rather, these documents endeavor to provide the available evidence. Just as an asymptomatic patient with low-risk ischemia and 1-vessel obstructive coronary disease may initially prefer a percutaneous coronary intervention procedure based on preexisting knowledge or conceptions, another patient with critical widespread 3-vessel coronary disease may prefer not to undergo revascularization based on exactly opposite pre-existing knowledge or conceptions. As such, the AUC are aimed at providing the clinician and patient the best available data and clinical consensus on revascularization care (based on symptoms/syndrome, anatomy, degree of ischemia, and medical therapy) so that a discussion to inform, educate, and then elicit patient preferences may be had. These decisions and practice patterns are then aggregated into population-based reports to centers to ensure they are consistent in who is offered revascularization.
Finally, the Drs. Kereiakes and Stone assert that the AUC are aimed more at overuse than underuse. Reviewing the ratings data for the 180 clinical scenarios demonstrate that the majority of the criteria is rated as appropriate, with a minority being rated as inappropriate with the existing published literature demonstrating low rates (Ͻ15%) of elective percutaneous coronary interventions with this categorization from multiple data sources. As stated, the AUC goal is to emphasize neither underuse nor overuse, but rather appropriate use. In this regard, Drs. Kereiakes and Stone are correct that evaluation of event rates from the uncertain group in the study by Ko et al. (4) demonstrates that 23 (15.3%) patients who did not undergo revascularization had died or had recurrent acute coronary syndromes at 3 years compared with 14 (8%) who underwent revascularization, potentially representing underuse in an underpowered observation. However, as a matter of perspective, readers should also note in the inappropriate categorized patients who did not undergo revascularization, 16 (9.4%) died or had recurrent acute coronary syndromes at 3 years compared with 20 (14.2%) who did undergo revascularization, almost the exact same numerical finding in the opposite direction of the uncertain group, potentially demonstrating overuse with harm in an underpowered observation. Hence, the report by Ko et al. (4) does provide
